Grape King BioTPE:1707 -0.11%78 Gross Margin % is 76.47% as of Dec. 2025, which is 6% below its 10-year median of 80.95. GuruFocus rates TPE:1707 with a GF Score™ of 78/100 and a GF Value™ of NT$144.03 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 938 Drug Manufacturers companies, Grape King Bio ranks better than 87.74% on this metric.
Grape King Bio Ltd gross margin has been in long-term decline. The average rate of decline per year is -1.6%.
The historical rank and industry rank for Grape King Bio's Gross Margin % or its related term are showing as below:
TPE:1707'
s Gross Margin % Range Over the Past 10 Years
Min: 75.08 Med: 80.95 Max: 86.22
Current: 75.08
During the past 13 years, the highestGross Margin % of Grape King Bio was 86.22%. The lowest was 75.08%. And the median was 80.95%.
TPE:1707's Gross Margin % is ranked better than 87.74% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs TPE:1707: 75.08
Grape King Bio had a gross margin of 76.47% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Grape King Bio was -1.60% per year.
Grape King Bio (TPE:1707) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Grape King Bio had a gross margin of 76.47% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Grape King Bio Gross Margin % Related Terms
Grape King Bio Gross Margin % Historical Data
* Premium members only.
The historical data trend for Grape King Bio's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Grape King Bio's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Grape King Bio (TPE:1707) has a Gross Margin % of 76.47% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Grape King Bio and its competitors. This is near median its historical median of 80.95. Over the past decade, Grape King Bio's Gross Margin % has ranged from 75.08 to 86.22. According to the industry distribution chart, Grape King Bio ranks #115 out of 938 companies in the Drug Manufacturers industry, placing it in the top 12.3%.
Is Grape King Bio's Gross Margin % too high?
Grape King Bio's current Gross Margin % of 76.47% is near median its 10-year median of 80.95. Over the past 10 years, this metric has ranged from a low of 75.08 to a high of 86.22. The Drug Manufacturers industry median Gross Margin % is 48.54. Grape King Bio's value of 76.47% is 57.5% above this industry median. Based on the distribution chart, Grape King Bio ranks #115 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grape King Bio has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grape King Bio ranks #115 out of 938 companies for Gross Margin %. This places Grape King Bio in the top 12% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Grape King Bio's value of 76.47% is 57.5% above this benchmark. Historically, Grape King Bio's own Gross Margin % has ranged from 75.08 to 86.22 over the past decade. While the company's 10-year median is 80.95 vs. the industry median of 48.54, Grape King Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grape King Bio's current Gross Margin % of 76.47% is 57.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Grape King Bio and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grape King Bio's current Gross Margin % is 76.47%, which is near median its own 10-year median of 80.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Possible Value Trap. The stock's GF Value™ is NT$144.03, compared to a current price of NT$91.00 — trading 36.8% below its estimated fair value. The current Gross Margin % is 76.47%, which is near median its 10-year median of 80.95 and 57.5% above the Drug Manufacturers industry median of 48.54. Grape King Bio's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current Gross Margin % is 76.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grape King Bio (TPE:1707) Overvalued in 2026?
Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued.
The current stock price of NT$91.00 is trading 36.8% below its estimated GF Value™ of NT$144.03.
GuruFocus considers Grape King Bio to be Possible Value Trap.
Key valuation signals for TPE:1707:
Gross Margin %: 76.47% (near median its 10-year median of 80.95)
GF Value™: NT$144.03 vs. price of NT$91.00 (36.8% below fair value)
Industry Position: 57.5% above the Drug Manufacturers median (#115 of 938)
No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
78GF Score
Get the complete analysis for TPE:1707
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1707 has been successfully added to your 
